title: [Management of vitamin K antagonists in the elderly].
abstract: Elderly patients of 80 years and above are commonly frail, due to substantial comorbid conditions and numerous medications. Managing elderly patients receiving vitamin K antagonists (VKA) is challenging because those patients are at high risk of both thrombosis and bleeding. Special considerations on the choice of the VKA drug, dosing and monitoring have to be taken into account in the elderly in order to avoid over-anticoagulation and to minimize the haemorrhagic risk which consequences may be dramatic or fatal in this age group. In these patients, INR monitoring is crucial, especially at the start of treatment. The use of dosing algorithms specifically developed for elderly patients allows to decrease over-anticoagulation during the initiation period. INR has to be monitored more frequently in case of acute illness or in case of modification of the associated drugs. Patient information and education are of great importance, even in geriatric patients and has been shown to improve the quality of anticoagulation. Even though the use of direct oral anticoagulants is currently expanding, prescribing VKA in elderly patients in whom the prevalence of severe renal insufficiency remains up to date.
authors.affiliation: Service d'hématologie biologique, Hôpital européen Georges Pompidou (AP-HP), Paris, France.
authors.forename: Tiphaine
authors.initials: T
authors.lastname: Belleville
authors.affiliation: Court séjour gériatrique, Hôpital Charles Foix, Ivry-sur-Seine, France, Inserm UMR S765, Sorbonne Paris Cité, Université Paris Descartes, Faculté des Sciences pharmaceutiques et biologiques, Paris, France.
authors.forename: Éric
authors.initials: É
authors.lastname: Pautas
authors.affiliation: Service d'hématologie biologique, Hôpital européen Georges Pompidou (AP-HP), Paris, France, Inserm UMR S765, Sorbonne Paris Cité, Université Paris Descartes, Faculté des Sciences pharmaceutiques et biologiques, Paris, France.
authors.forename: Pascale
authors.initials: P
authors.lastname: Gaussem
authors.affiliation: Service d'hématologie biologique, Hôpital européen Georges Pompidou (AP-HP), Paris, France, Inserm UMR S765, Sorbonne Paris Cité, Université Paris Descartes, Faculté des Sciences pharmaceutiques et biologiques, Paris, France.
authors.forename: Virginie
authors.initials: V
authors.lastname: Siguret
mesh_terms: D015110:4-Hydroxycoumarins / Q000008:administration & dosage / Q000009:adverse effects*; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D054796:Drug Dosage Calculations; D006470:Hemorrhage / Q000139:chemically induced* / Q000517:prevention & control*; D006801:Humans; D007192:Indenes / Q000008:administration & dosage / Q000009:adverse effects*; D008991:Monitoring, Physiologic; D013927:Thrombosis / Q000188:drug therapy / Q000453:epidemiology; D014812:Vitamin K / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors*
chemical_list: D015110:4-Hydroxycoumarins; D000925:Anticoagulants; D007192:Indenes; C011664:antivitamins K; D014812:Vitamin K
keywords: INR; elderly; oral anticoagulant; vitamin K antagonist